Qilian International Holding Group Ltd. (中国)

The Company engages in the research, development, and production of active pharmaceutical ingredients, traditional Chinese medicine derivatives, and other by-products in China.
The Company has three operating segments: Oxytetracycline Licorice products and TCMD, Fertilizer, Heparin products and Sausage casing.
The Company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil s chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth.
2019 The Company s a Cayman Islands exempted company incorporated on February 7, 2019 as a holding company to develop business opportunities in the People's Republic of China. The Company s a wholly-owned subsidiary of Qilian International formed in accordance with the laws and regulations of Hong Kong on January 30, 2019.
2021 The Company is ordinary Shares commenced trading on the Nasdaq Global Market under the symbol “QLI.” in January 12, 2021.